KEYNOTE-604 and ECOG-ACRIN 5161 Trials for ES-SCLC


Mark Socinski, MD: With both of those being anti–PD-L1 antibodies, I’m going to ask Dr Liu, we are coming off the tail of our first virtual ASCO [the American Society of Clinical Oncology annual] meeting this year. And at that meeting we saw the presentation of 2 trials with PD-1 inhibitors, KEYNOTE-604 with pembrolizumab, and the ECOG-ACRIN 5161 trial, which was actually a phase 2 trial with nivolumab. Can you walk us through those and give us your impressions?

Stephen Liu, MD: Yes. These are 2 randomized studies and we saw results for the first time. The phase 3 trial you mentioned, KEYNOTE-604, was presented by Charles Rudin, [MD]. This was a very well-designed randomized, placebo-controlled large phase 3 trial. It included patients with previously untreated stage IV small cell lung cancer. All patients received platinum/etoposide, allowed either carboplatin or cisplatin, with a 1:1 randomization to concurrent pembrolizumab or placebo, followed by maintenance [pembrolizumab] or placebo. The study had 453 patients, of note, the vast majority, about 70%, received carboplatin. And it had dual primary end points of progression-free survival [PFS] and overall survival [OS]. What we saw at ASCO 2020 was the final analysis, and in that analysis KEYNOTE-604 was positive in that it hit its progression-free survival end point. The PFS favored pembrolizumab a median of 4.8 from 4.3 [months], the hazard ratio there was 0.73, the 1-year PFS rate from 5% with placebo to 15% with [pembrolizumab].

Unfortunately, overall survival did not cross the threshold for superiority. There was a numeric difference, median from 9.7 to 10.8 [months], hazard ratio of 0.80, but it did not cross that statistical threshold for a positive OS benefit. It’s interesting, if you take away 1 patient who inadvertently received the wrong treatment, it was a positive trial, just to show how close it was. We learned from KEYNOTE-604 there is activity there, comparable, in the same ballpark, as we saw with PD-L1 in IMpower133 for atezolizumab, and in CASPIAN for durvalumab. But unfortunately, this will not impact practice because it did not improve survival; while the trend was encouraging, it didn’t quite get there.

The ECOG-ACRIN 5161 was a randomized phase 2, through the cooperative group. It accrued remarkably fast, and this study looked at platinum/etoposide with or without nivolumab. No placebo, choice of platinum, this was a smaller study, a phase 2, 160 patients, and this study accrued in 7 months. Primary end point was progression-free survival, and that improved with nivolumab from 4.7 to 5.5 [months]. It’s a hazard ratio of 0.68. Even though a relatively modest size study, it was able to show a PFS benefit and was able to show a survival benefit. The OS hazard ratio there was 0.73. This was a smaller phase 2 positive for both PFS and OS. In a world where we have multiple randomized phase 3 trials showing an OS benefit with atezolizumab, durvalumab, unfortunately, no immediate impact in our clinic.

Transcript Edited for Clarity

Related Videos
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Jobelle Baldonado, MD
Joshua K. Sabari, MD, an expert on lung cancer, presenting slides
Chul Kim, MD, MPH
Salman R. Punekar, MD, Mayo Clinic
Federico Cappuzzo, MD
Pasi A. Jänne, MD, PhD, director, Lowe Center for Thoracic Oncology, director, Belfer Center for Applied Cancer Science, director, Chen-Huang Center for EGFR Mutant Lung Cancers, senior physician, David M. Livingston, MD, Chair, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Edgardo S. Santos Castillero, MD, FACP
Joshua K. Sabari, MD